within Pharmacolibrary.Drugs.ATC.C;

model C01BD07
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.04,
    Cl             = 0.0021666666666666666,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 1.4,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 10.200000000000001,            
    Vdp             = 5.7,
    k12             = 200,
    k21             = 200
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C01BD07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dronedarone is an antiarrhythmic medication used to treat atrial fibrillation and atrial flutter in adults. It is structurally related to amiodarone but developed to reduce adverse effects such as thyroid and pulmonary toxicity. Dronedarone is approved and in current clinical use for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers after multiple oral doses; typical PK profile as per published studies.</p><h4>References</h4><ol><li><p>Baek, IH (2019). Dose proportionality and pharmacokinetics of dronedarone following intravenous and oral administration to rat. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 49(6) 734–739. DOI:<a href=&quot;https://doi.org/10.1080/00498254.2018.1496369&quot;>10.1080/00498254.2018.1496369</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29962267/&quot;>https://pubmed.ncbi.nlm.nih.gov/29962267</a></p></li><li><p>Kim, MS, &amp; Baek, IH (2018). Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 111 13–19. DOI:<a href=&quot;https://doi.org/10.1016/j.ejps.2017.09.029&quot;>10.1016/j.ejps.2017.09.029</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28942006/&quot;>https://pubmed.ncbi.nlm.nih.gov/28942006</a></p></li><li><p>Jardan, YA, &amp; Brocks, DR (2016). The pharmacokinetics of dronedarone in normolipidemic and hyperlipidemic rats. <i>Biopharmaceutics &amp; drug disposition</i> 37(6) 345–351. DOI:<a href=&quot;https://doi.org/10.1002/bdd.2016&quot;>10.1002/bdd.2016</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27194397/&quot;>https://pubmed.ncbi.nlm.nih.gov/27194397</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C01BD07;
